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ABSTRACT
Retinoblastoma has the unique capacity to accelerate its own intra-ocular propagation by adopting semi-solid
or even liquid growth properties through seeding. Until recently, the presence of any degree of seeding was
mostly incompatible with successful conservative management, due to the multiresistant nature of the seeds.
Surprisingly, this well-recognized retinoblastoma behavior has not undergone any detailed description of
seeding patterns and anatomic sites. In this paper, we describe the phenotypic variability of seeds across the
four possible intraocular seeding compartments and classify them into three fundamental types: namely dust,
spheres, and clouds. We also provide an overview of the different therapeutic strategies developed for seeding,
with special attention to intravitreal chemotherapy as the treatment of choice for vitreous and retro-hyaloid
seeding. Finally, we propose criteria to enable assessment of the response to treatment by reporting seed
regression patterns, as well as a clinical grading system for the retinal toxicity observed following intravitreal
melphalan.
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DEFINITION
Retinoblastoma seeding refers to any type of tumor
dispersion into an adjacent liquid or semi-liquid
compartment. Seeding is typically seen in advanced
intra-ocular retinoblastoma and represents a major
determinant for eye grouping at presentation (see
International Classification of Retinoblastoma:1
groups C, D, and E). It can also be a feature observed
in extra-ocular retinoblastoma (see Retinoblastoma
Staging System:2 stages IIN3 and IVb3).
THE SEEDING ANATOMIC SITES
Intra-ocular retinoblastoma (Figure 1A) may seed into
four distinct anatomic sites (Figure 1B–E): (1) tumor
dispersion into the vitreous gel following endophytic
disruption of the internal limiting membrane (ILM)
and hyaloid at tumor apex; (2) tumor suspension
spreading into the retro-hyaloidal space secondary to
endophytic disruption of the ILM at tumor base alone,
and partial or complete posterior vitreous detach-
ment; (3) tumor suspension into the subretinal space
created by exophytic growth; and (4) tumor suspen-
sion into the aqueous fluid of the posterior and
anterior chambers secondary to disruption of the
anterior hyaloid. In addition, retinoblastoma growth
extending anteriorly to the ciliary body can cause a
contaminated supraciliary effusion.3 Extra-ocular ret-
inoblastoma may seed in two different anatomic sites:
(1) anteriorly into the amniotic fluid in the case of fetal
fungating retinoblastoma,4,5 and (2) posteriorly in the
case of retro-laminar invasion with seeding into the
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circulating subarachnoidal fluid and progress from
localized micrometastasis (stage IIN3) with negative
lumbar punction cytology6 to diffuse CNS disease
with leptomeningeal carcinomatosis (stage IVb3).
Alternatively, direct seeding into the CSF can occur
from a pinealoblastoma or a parasellar tumor in the
case of trilateral retinoblastoma.7
SEED CLASSIFICATION
There are three distinct seeding patterns in retino-
blastoma (Figure 2), namely (1) dust formation
resulting from cellular infiltration (Figure 2A), (2)
cloud formation resulting from translocation of the
primary tumor content (Figure 2C), and (3) sphere
formation resulting indirectly from clonal expansion
of the dust (Figure 2B) or the cloud, or directly by
sprouting of the primary retinal tumor (Figure 2D
and E). The spheres may be either translucent
(Figure 2H and I) or may have a whitish center
(necrosis) surrounded by translucent mono- or multi-
layered tumor cells (Figure 2F–K).
The three seeding types can occur in any of the four
retro-hyaloidal, vitreous, subretinal, or intra-cameral
seeding compartments. The tumor appearance and
FIGURE 2. Seeding patterns of retinoblastoma: (A) dust following the apical disruption of the ILM/hyaloid complex; (B) spheres
resulting either from clonal expansion of dust (or cloud) or (D and E) from sprouting; (C) cloud(s) following massive disruption of the
ILM/hyaloid complex. Ophthalmoscopic aspect of vitreous seeds (F–I) white or translucent with a whitish (necrotic upon
histopathology and hyper-reflective upon OCT) or translucent center (cystic on OCT, cf. Figure 7E and F). Histopathologic aspect of
vitreous seeds (J and K) mono- or multilayered tumor cells surrounding necrotic material.
FIGURE 1. Schematic view of the natural history of intra-ocular retinoblastoma growth with respect to the invasion of five clinically
recognizable anatomic sites: (A) retina; (B) retro-hyaloid space; (C) subretinal space; (D) vitreous cavity; (E) posterior and anterior
chambers.
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growth patterns will differ according to the physical
nature of the invaded compartments. Tumor spread
into the viscous vitreous gel initially resembles dusty
(loose cellular spread) or cloudy (dense cumulus-like
spread) infiltrates, resulting from localized (Figures 3
and 4) versus massive ILM/hyaloid disruption,
respectively (Figure 5). The vast majority of the cells
composing dust or clouds will not survive the hypoxic
environment of the newly invaded compartment
unless they develop the necessary metabolic repro-
gramming8 and/or resistance to anoikis.9 Based on
our observations in the vitreous, the capacity for
clonal expansion of the surviving cells can be divided
into two populations with distinct phenotypic behav-
iors: (1) cells capable of adherence-independent
growth forming free floating spheres (Figure 3D–H)
and (2) cells under the control of adherence-
dependent growth leading to the formation of sea-
weed-like or oval-shaped tumors anchored to the
internal face of the posterior hyaloid (Figure 4A–F).
Under the effect of gravity, the free-floating vitreous
tumors slowly migrate and tend to accumulate infer-
iorly and to project anteriorly to the ora serrata.
Finally, tumor spread into the retro-hyaloid (Figure 6)
or subretinal (Figure 7) compartments is also asso-
ciated with the formation of spheres, which differ
from those in the vitreous by their ability to rapidly
migrate according to gravitational stimuli, tending to
accumulate inferiorly posterior to the vitreous base
(Figure 6H and I) or the ora serrata (Figure 7C),
respectively. In contrast to the free-floating vitreous
seeds, the pre-hyaloid and retro-hyaloid seeds are all
located at the same level, attach to the internal face of
the hyaloid and ILM, respectively and tend to coalesce
FIGURE 3. Characteristics of endophytic seeding into the vitreous cavity: (A and B) fine dust visible around the retinal tumor;
(C) dust originating from the upper tumor; (D and E) multiple free-floating spheres growing within the initial dust, (F) sphere
formation in the same patient 4 months after focal treatment of the retinal tumors. Note the concentration of localized spheres in the
upper quadrant and their migration inferiorly; (G and H) diffuse migration of spheres projecting anterior to the ora serrata, (I) spheres
anterior to the ora serrata, masking the corpus ciliaris except the pars plicata and corresponding UBM imaging (J).
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FIGURE 4. Characteristics of prehyaloid seeding, (A–H) partially coalescent seeds attached to the internal face of the posterior
hyaloid; (I and J) OCT of prehyaloid seeds (same patient as G and H) showing signs of fragmentation and hyper-reflectivity and
progressive hyaloid detachment following intravitreal injections of melphalan.
FIGURE 5. Localized (A–C) and diffuse (D–F) cloud formation with concomitant clonal growth (F). The cloud can be multiple as a
result of iterative translocations of tumor material into the vitreous.
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(Figures 4 and 7C and D). The retro-hyaloid seeds
with adherence-independent properties behave either
as free spheres (Figure 8E–H) or pavementous-like
seeds in the meniscus of liquid created by a partial
posterior hyaloid detachment (Figure 8A and B), in
contrast with the hemispheric or oval-shaped aspect
of seeds with adherence-dependent growth. The
subretinal seeds may be free running (Figure 9A and
B) or fixed to the external retinal surface (Figure 9C
and D) or to the retinal pigment epithelium (Figure 9F
and G). Finally, a large ILM disruption at tumor base
can be followed by a massive transfer of tumor
material into the retro-hyloidal space, creating a
position-dependent circular level (Figure 10) masking
the optic nerve head. The same phenomenon of cloud
formation can occur under a detached retina, leaving
the optic nerve head visible (Figure 7G–L).
With tumor invasion of the aqueous fluid of the
anterior segment following disruption of the
anterior hyaloid, the clinical features can be divided
into free-floating spheres or tumor cells, possibly
forming a pseudo-hypopion, or tumors attached to
the iris (spheres) and corneal endothelium (pavemen-
tous-like growth) (Figure 11).
THE THERAPEUTIC CHALLENGE OF
SEEDING
While solid vascularized retinal tumors are easily
accessible to various treatment modalities, the tumoral
avascular counterpart involving the other ocular sites
are either poorly controlled by conventional therapies
or beyond any conservative treatment as in the case of
anterior segment invasion (absolute criteria for enu-
cleation). Lack of response of these avascular tumors
may be explained by the inability of the present
routes of antimitotic administration to achieve
FIGURE 6. Retro-hyaloid seeding following partial (A–F) or complete (G–H) hyaloid detachment; (I) tumor at presentation with
subtotal hyaloid detachment sparing the 6 o’clock meridian. The white arrow indicates the ora serrata and the white asterisks the
anterior extension of the hyaloid detachment corresponding to the posterior border of the vitreous base.
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tumoricidal concentrations in the corresponding eye
compartments. In addition, these tumors are virtually
inaccessible to focal treatments and are highly radio
resistant due to their hypoxic nature.
Primary Vitreous Seeding
The presence of diffuse vitreous seeding is a hallmark
of advanced retinoblastoma characterizing group D
eyes in the International Classification of
Retinoblastoma,1 a feature typically necessitating
enucleation or external beam radiotherapy. Reese10
already noted that the prognosis of eyes with vitreous
seeding at presentation was ‘‘very unfavorable’’ and
classified them in the most severe group (Vb).
Historically, the best salvage rates reported with
first-line external beam radiotherapy barely exceeded
50% for group Vb eyes.11 The shift to first-line
systemic (IVC) chemotherapy (with or without
FIGURE 7. Characteristics of subretinal seeding (A–D) partial and total retinal detachment with subretinal seeding showing typical
accumulation inferiorly at the ora serrata (Figure 9C white triangles) and tending to coalesce. (G–K) Subretinal cloud with position-
dependent ophthalmoscopic contours and spirit level. The white asterisk highlights the limit of cloud extension in lateral decubitus.
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pre-chemo cryorupture of the external hemato-retinal
barrier to increase the vitreous drug concentration)
failed to improve eye survival of advanced retino-
blastoma with only 47% avoiding enucleation and
EBR at 5 years follow-up.12 In a recent study on 55
group D eyes, IVC and focal therapy resulted in
Kaplan–Meyer estimates of eye survival to be 68% at
5 years, with additional low dose (36 Gy) intensity-
modulated radiation therapy being necessary in
44% of the eyes.13 The probability of ocular sal-
vage without EBR in eyes with vitreous seeding
significantly increased to 64% at 2 years follow-up
after the introduction of first-line intra-arterial chemo-
therapy.14 However, this figure may be optimistic
since Suzuki et al.15 reported an eye preservation rate
of 45% in group D eyes using the same approach with
a longer follow-up (79 months).
Secondary Vitreous Seeding
Vitreous seeding may also appear during the treat-
ment course in eyes devoid of vitreous seeds at diag-
nosis.16 A possible iatrogenic component is plausible
FIGURE 8. Retro-hyaloid seeding: (A–D) free pavementous-like seeds changing position with eye movements within a very shallow
retro-hyaloid aqueous space; (F–H) cystic sphere rolling at the posterior pole. See the position of the seed highlighted by the white
triangle (E and G) with respect to the vascular bifurcation (white asterisk).
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since the occurrence of secondary vitreous seeding is
observed in only 10% of eyes treated with chemother-
apy alone versus 21% in eyes treated with thermo-
chemotherapy.16 Another cause of secondary vitreous
involvement is the sudden vitreous dispersion of
large tumors shortly after the initiation of chemother-
apy due to a necrotic disruption of the internal
limiting membrane.17 However, given such a compli-
cation, it is mandatory to distinguish active vitreous
seeding from inactive mostly calcified seeding.18
Vitreous recurrence in eyes with vitreous seeds
at presentation is a frequent finding after chemor-
eduction. The mean interval to first and last recurrent
seedings is 14 months (3–37 months) and 21 months
(6–50 months), respectively.19 Not surprisingly, the
probability for ocular survival in the case of recurrent
and/or refractory vitreous seeding is only 20–
24%.16,19 We published a slightly better prognosis of
76% tumor control for localized vitreous seeding
confined to the apex of recurrent retinal tumors
accessible to ruthenium brachytherapy.20 Vitreous
seeding recurring after EBR has a worse prognosis
with only 2% salvage following a second course of
EBR.21 Intra-arterial chemotherapy as salvage treat-
ment for recurrent vitreous seeding was recently
granted a 50–76% eye survival rate at 2 years.14
FIGURE 9. Subretinal seeding. (A and B) free subretinal sphere (white asterisks and triangles show the mobility of the seed). (C and
D) Fixed subretinal seeds attached to the external retina as seen by ophthalmoscopy. (D) UBM. The white arrow highlights the oral
insertion of the detached retina. (E) OCT showing a seed attached to the external retina. (F and G) OCT showing retinal pigment
epithelium attachment of subretinal seeding following retinal reattachment.
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Despite tremendous advances in the conservative
management of advanced retinoblastoma, the major
cause of failure remains the persistence or recurrence
of resistant vitreous seeding. Pharmacokinetic studies
in the preclinical model have recently shown that if
the novel routes of administration such as intra-
arterial chemotherapy have greatly improved the
ocular penetration of the drugs compared with sys-
temic chemotherapy, the achieved vitreous concentra-
tion is barely tumoricidal and does not last long
enough for tumor control. The Cmax obtained in the
vitreous following intra-arterial infusion of melphalan
remains lower than the 50% inhibiting concentration
(IC50).22
To circumvent this concentration problem, intravi-
treal delivery of chemotherapy would offer the high-
est drug bioavailability in the vitreous. Despite the
obvious risk of tumor spread, this invasive approach
was first explored by Ericson and Rosengren23 who
performed intravitreal injections of thiotepa as a
heroic treatment in six eyes with recurrent vitreous
disease, achieving success in three eyes with a mean
follow-up of only 8 months. This initial experience
was pursued more than 30 years later by Seregard
et al.,24 who treated three eyes using the same
approach followed by vitrectomy with a mean
follow-up of 54 months, avoiding enucleation in two
eyes. More recently, Kivela et al. reported the use of
intravitreal methotrexate in five eyes with relapse
following chemoreduction, only two of them having
vitreous seeding.25 Each eye received 20–27 injections
of methothrexate over a period ranging between 10
and 12 months. Two eyes were enucleated, including
one eye with vitreous seeds and one eye required
external beam irradiation.
The literature owes to Kaneko and Suzuki26 the
pioneering role in IViC, for publishing the largest
series of IViC treatments in eyes with retinoblastoma.
These authors performed intravitreal injections of 8 mg
of melphalan combined with ocular hyperthermia for
vitreous tumor and claimed an eye-preservation rate
of 51% at 50 months follow-up. The choice of
melphalan was based on in vitro studies by Inomata
and Kaneko,27 who found this drug to be the most
efficient among the 12 tested, achieving complete
suppression of colony formation at a concentration of
4 mg/ml. Preclinical studies in albino rabbits28 have
established that melphalan at a vitreous concentration
of 5.9 mg/ml is functionally and structurally non-toxic
to the retina. When extrapolated to the human
vitreous volume, the injected rabbit dose corresponds
to 20–30 mg which is to be injected depending on the
patient’s age.
Since their initial pioneering report, Kaneko and
Suzuki29 have performed 896 IViCs in 237 eyes of 227
patients. They reported the occurrence of extraocular
subconjunctival extension in one eye (0.4%), which
had anterior chamber involvement and dense vitreous
seeds. The patient received adjuvant chemotherapy
after enucleation and is reported to be in complete
remission. Among the 10 patients (4.4%) who devel-
oped metastases, one was potentially due to IViC
(0.4%). However, it should be emphasized that the
Japanese injection procedure significantly differs from
our protocol (see below). Specifically, the absence of
well-defined contraindications, as well as the lack
of antireflux measures and needle tract sterilization,
despite injected volumes of 0.1–0.2 ml, might have
contributed to the incidence of the reported adverse
events.
FIGURE 10. (A–H) Retro-hyaloid cloud with typical position-dependent ophthalmoscopic contours and spirit level on ultrasonog-
raphy (white asterisks: detachment of the posterior hyaloid).
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FIGURE 11. Anterior and posterior chamber seedings. (A and B) spheres in the anterior chamber; (C and D) pseudo-hypopyon
(anterior chamber equivalent of a cloud); (E and F) UBM showing spheres invasion of the posterior chamber (E) and spheres and
plaque formation in the anterior chamber (F); (G–I) HE staining of seeds in the anterior segment showing spheres and tumor plaques
growing at the corneal endothelial surface (G and I).
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Conditional Rehabilitation of Intravitreal
Chemotherapy
Until recently, the intravitreal approach remained
virtually banished from the therapeutic armamentar-
ium against retinoblastoma, due to the risk of loco-
regional and systemic tumor spread. This risk results
from two distinct underlying mechanisms, the one
active post-operative and the other passive per-
operative. Active post-operative exteriorization may
occur via tumor growth along a contaminated surgical
wound, or in consequence to co-localization of the
entry site with a parietal tumor. Passive per-operative
tumor spread may occur due to vitreous incarceration
or spilling of tumor cells adherent to surgical instru-
ments when removed from the eye, or to the reflux
of contaminated humors secondary to variations of
intraocular pressure.
In the light of these data, we decided to revisit the
feasibility of injecting the chemotherapeutic agent
directly into the vitreous cavity through the pars
plana as the best way to achieve the appropriate drug
concentration. As intravitreal injection constitutes a
violation of the ‘‘metastatic grace period’’ typically
operated during conservative management of intrao-
cular retinoblastoma, reappraisal of this route of
administration was subjected to three pre-requisites
susceptible to prevent tumor spread (1) to validate a
method reliably assessing the anterior extension of
retinoblastoma, hidden in the dead angle of ophthal-
moscopy (anterior hyaloid and posterior chamber), in
order to secure the needle entry site; (2) to delineate
eligibility criteria for the procedure; and (3) to
describe a safety-enhanced injection technique.
Prevention of Tumor Spread
As a first step, we tested the value of ultrasonic bio-
microscopic (UBM) imaging of the anterior segment,
using a 35 m Hz transducer, to predict the safety of a
pars plana route of administration. This allowed us to
show that tumoral contamination of the posterior
chamber can be assessed by UBM with high sensitiv-
ity and specificity even in the absence of anterior
chamber involvement.30
Our next step was to profile eligibility criteria for
intravitreal injection by parametring all risk factors for
tumor spread and then by designing an injection
technique minimizing the addressed risks.31 To be
effective in preventing extra-ocular tumor spread, the
injection procedure should minimize both active and
passive mechanisms of exteriorization.
Concerning the prevention of active mechanisms
of exteriorization, UBM-based contra-indications to
IViC were identified. IViC was considered a threat for
survival, and thus an absolute contra-indication, in
the case of parietal tumor or seeding co-localizing
with the entry site, especially if the posterior chamber
is invaded. IViC was considered as a threat for eye
survival, and thus a relative contra-indication, in the
case of anterior hyaloid or retinal detachment at the
meridian of the entry site. The risk here is to convert
(a) vitreous seeding to anterior segment seeding
through the perforated hyaloid, or (b) exudative
retinal detachment to the rhegmatogenous form.
This is also the reason why we excluded other
injection routes of administration other than the pars
plana, such as the trans-corneal approach. The tech-
nique of injection through the peripheral cornea and
iris root specifically creates not only perforation of the
cornea but also perforation of the iris and anterior
hyaloid. If the first can be secured by cryotherapy, the
risk of contamination remains for the latter two, the
worst being the creation of a communication between
the vitreous cavity and the posterior chamber. The
danger is real since anyone who has performed
intravitreal injections knows that vitreous incarcer-
ation through the sclera can occur while retracting the
needle.
The second level of tumor spread prevention is
aimed at addressing all risk factors linked to the per-
operative passive mechanisms of exteriorization, i.e.
the gradient of pressure across the sclera, the size and
the number of surgical entries, and the duration of
surgery. This led us to develop a safety-enhanced
injection technique,31 consisting of an antireflux tech-
nique and sterilization of the needle tract. Specifically,
we first create a transient hypotony by anterior
chamber paracentesis, aspirating the same volume
as that to be injected into the vitreous. A 32 G needle
mounted on a tuberculin syringe is then introduced
perpendicularly 2.5–3.5 mm from the limbus at the
desired meridian opposite the seeds, through the
conjunctiva and sclera viewed under the surgical
microscope, until the needle tip reaches the center of
the vitreous cavity immediately behind the lens (with
care not to inject in a retro-hyaloid space). The injected
dose is 20 mg in most cases but can be cumulatively
increased by 2–4 mg up to 30 m g for each of the
following situations: (1) age over 2 years; (2) diffuse
nature and/or high density of the seeding; (3) previ-
ous intra-arterial exposure to melphalan; and (4)
relapse after previous IViC. Upon removal of the
needle three cycles of freeze and thaw cryo applica-
tions are given at the injection site. The eye is then
carefully shaken with forceps in all directions to




Using the above-mentioned technique, we reported
the first case series showing the efficacy and the safety
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of intravitreal chemotherapy (IViC) in retinoblastoma
patients presenting with vitreous disease.32 Twenty-
three consecutive heavily pretreated patients present-
ing vitreous seeding and eligible for IViC were
included in this retrospective non-comparative
study. The study population consisted of 18 bilaterally
affected patients, 10 of whom had only one eye, and
five patients with unilateral retinoblastoma. IViC was
proposed as an alternative to external beam irradi-
ation or enucleation for recurrent (74%) or refractory
(26%) seeds. Almost two-thirds of this population
received intra-arterial melphalan chemotherapy
before IViC. Overall success with control of vitreous
seeds was achieved in 21 of 23 eyes (91%) after a mean
number of four injections. Globe retention was
achieved in 87% of cases with only two eyes
enucleated for progressive disease and one for phthi-
sis bulbi unrelated to IViC. All retained eyes were in
complete remission, and there were no cases of orbital
or systemic retinoblastoma recurrence over a mean 22
months’ follow-up. The Kaplan–Meier estimate of
ocular survival rates at 2 years was 84.14% (95% CI
62.48–95.28%). All patients were alive without evi-
dence of extraocular spread (95% CI 82.19–100%). We
have now extended the follow-up of this initial cohort
of 20 conserved eyes with a mean tumor-free eye
survival (unpublished data) of 32 months (17–42
months).
Retinal toxicity appeared to be limited to the site of
injection in the form of a peripheral well-demarcated
salt-and-pepper retinopathy in 10 eyes (43%). In fact,
this local toxicity confined to the site of a higher
concentration of melphalan along the needle passage
serves to increase the security level of the procedure.
There was no ophthalmoscopic or fluoroangiographic
evidence of retinal toxicity at other locations.
Similarly, we detected no optic coherence tomography
(OCT) changes within the macula after IViC (unpub-
lished data). A transient localized vitreous hemor-
rhage in two eyes (8.5%) was the only ocular
complication observed. Specifically, IViC was not
found to cause corneal endothelium insufficiency,
cataract (one case was radiation induced), uveitis,
endophthalmitis, or retinal detachment.
For the first time, the eye retention rate of the worst
retinoblastoma eye group (group D and all cases with
recurrent or refractory vitreous seeding) appeared to
parallel that of groups A–C without external beam
radiotherapy.
Clinical guidelines and rules conditioning the prescrip-
tion of IViC for vitreous and/or retro-hyaloid seeding
(a) the tumoral nature of the seeding is unequivo-
cal and differentiated from other mimicking
conditions, such as old vitreous hemorrhage or
vitritis;
(b) the tumoral viability of the seeding is obvious,
which can sometimes require an observation
period to document the vitreous growth;
(c) all UBM-based contra-indications have been ruled
out;
(d) finally, the retinal source of the seeding must be
identified and, if still active and accessible to focal
treatments, must be concomitantly eradicated.
If the retinal source is not amenable to focal
treatment, combined intra-arterial and intravitreal
chemotherapy may be considered.
RESPONSE MONITORING AND
REGRESSION PATTERNS
At each visit, the residual vitreous tumor burden is
reassessed and IViC is carried out every 7–10 d, up to
eight injections if a response can be documented, until
complete seed fragmentation and dispersion are
observed or complete response is achieved
(Figure 12). Complete response is established if the
seeds (1) completely disappear (vitreous seeding
regression type 0) or convert into (2) refringent and/
or calcified residues (vitreous seeding regression
type I), (3) amorphous often non-spherical inactive
residues with or without pigment (vitreous seeding
regression type II), or (4) a combination of the latter
two (vitreous seeding regression type III). An injection
of consolidation is usually given once complete
response is observed. IViC can be repeated if vitreous
recurrence occurs from another source.
Interestingly (unpublished data), the timing to
complete regression, regression type, number of
intravitreal injections, and total dose of melphalan
differ significantly among dust, spheres, and clouds.
The median number of injections is 3 (a median total
dose of 60 mg) in case of dust compared with 4 (107mg)
and 6 (203 mg) for spheres and clouds, respectively.
Similarly, the median time to complete regression is
0.5, 1.4, and 6.6 months for dust, spheres, and clouds,
respectively. Finally, the regression pattern was type 0
in 100% of dust, 90% of spheres (10% types I and II),
and 55% of clouds (45% types I, II, and III).
Clinical Grading of Retinal Toxicity
In our initial report,32 a localized peripheral salt-
and-pepper retinopathy was noted in 43% of the cases
at the site of injection. We propose a clinical grading
system to enable assessment of retinal toxicity. Retinal
toxicity grade I is defined as salt-and-pepper retinop-
athy no greater than 2 clock hours of peripheral retina
anterior to or at the equator. Grade II refers to any
retinopathy extending greater than 2 clock hours
anteriorly or at the equator. In grade III, the retinop-
athy extends posterior to the equator but sparing the
macula. In grade IV, the retinopathy is complicated by
a maculopthy, while grade V is characterized by a
pan-retinopathy with optic atrophy (Figure 13).
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FIGURE 13. Clinical grading system of retinal toxicity: (A) grade I, (B) grade II, (C) grade III, (D) grade IV, (E) grade V.
FIGURE 12. Regression patterns of vitreous seeding: (A) vitreous seeds prior to IViC, (B) partial response following first IViC
characterized by fragmentation of the spheres sometimes accompanied by a pseudo-growth, (C) further fragmentation after additional
injections before complete extinction. Complete response can be classified into complete disappearance (type 0), conversion into either
(D) calcified seeds (type Ia), (E) crystalline refringent dust (type Ib), (F) amorphous non-spherical (see asterisk) seeds (type II), or (F) a
combination of regression types I and II (type III).
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We believe that this complication is technique
related and can be minimized by (1) choosing a pars
plana entry site 3–3.5 mm from the limbus, (2) using
a 12-mm 32G needle placed centrally under the
operating microscope in the back of the lens to
avoid injecting close to the retina or in the retro-
hyaloid space, (3) performing a paracentesis of the
anterior chamber to promote the use of higher
injection volumes of diluted drug, (4) injecting sys-
tematically along the same meridian to avoid the
circular extension of the retinopathy, and (5) shaking
the eye in all directions to enable even distribution of
the drug. At least in our hands, the strict application
of these rules completely prevented the occurrence
of grades IV and V toxicity after more than 400
procedures.
CONCLUSIONS AND PERSPECTIVES
In our experience, the introduction of IViC (combined
with intra-arterial chemotherapy if the retinal source
of the seeding is not accessible to focal therapy) is
associated with an eye survival of 95% (paper in
preparation). In addition, external beam irradiation is
now virtually eradicated with no indication in the last
6 years of our practice.
Although IViC appears to offer a safe and efficient
salvage option, its validation awaits the results of
a prospective phase II clinical trial (EudraCT
number 2013-002006-31). Special attention will be
paid to long-term safety and retinal toxicity assessed
by electroretinogram, fluorescein angiography, optic
coherence tomography (OCT), and adaptive optics.
In a preliminary report, we have shown that
photopic ERG amplitudes were unchanged compared
with those recorded prior to the intravitreal injection
treatments.33
If validated, IViC will not only be useful as salvage
treatment for recurrent or resistant vitreous seeds but
also as a prophylactic measure in cases of iatrogenic
seeding after photocoagulation and plaque surgery, or
for group B eyes with ruptured internal limiting
membrane (as assessed by fluorescein angiography or
OCT, i.e. presumptive submicroscopic infraclinical
vitreous disease at presentation). In addition, con-
firmation of IViC safety will pave the way for the
development of trials with novel, possibly custo-
mized, molecules.
Finally, we want to emphasize that although IViC
does not replace standard treatment care for group C
and D eyes, we expect that the addition of front-line
IViC to state-of-the-art treatment in eligible group C
and D eyes may significantly reduce the exposure to
systemic or intra-arterial chemotherapy, as well as the
indications for EBR and/or enucleation.
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